GlassScriptPhysician profile
Luis A Gonzalez
NPI 1316047327
$20,303.40
in general payments reported to CMS, 2019-2025
42 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,165 · 2020: $4,605 · 2021: $4,858 · 2022: $2,973 · 2023: $2,831 · 2024: $1,653 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,991 · Consulting Fee: $700 · Education: $11.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,990.95 |
| Consulting Fee | $700.00 |
| Education | $11.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,473.23 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $3,114.67 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Cumberland Pharmaceuticals, INC. | $2,331.24 | 2019-2025 | Kristalose |
| Abbvie INC. | $2,008.20 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $1,368.28 | 2020-2021 | |
| Lilly USA, LLC | $977.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $727.54 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $621.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Redhill Biopharma INC. | $600.49 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Boehringer Ingelheim Pharmaceuticals, INC. | $555.08 | 2019-2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $440.51 | 2019-2023 | Trintellix |
| Horizon Therapeutics Plc | $417.89 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $402.27 | 2022-2025 | Seglentis, Zoryve, Livalo |
| Vanda Pharmaceuticals INC. | $349.70 | 2019-2023 | Hetlioz, Fanapt |
| Nestle Healthcare Nutrition INC. | $212.36 | 2020-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.